<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019965</url>
  </required_header>
  <id_info>
    <org_study_id>2016-785-099</org_study_id>
    <nct_id>NCT03019965</nct_id>
  </id_info>
  <brief_title>Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis</brief_title>
  <official_title>Efficacy and Safety of the Administration of Betalactam Antibiotics in Continuous or Extended Infusion Compared to Intermittent Infusion in Patients With Sepsis in Two Pediatric Third-level Care Hospitals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of the administration of betalactam antibiotics
      in prolonged infusion compared to intermittent infusion in children with sepsis. Half of
      participants will receive piperacillin/tazobactam, imipenem or meropenem in continuous or
      extended infusion, while the other half will receive piperacillin/tazobactam, imipenem or
      meropenem in intermittent infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is the leading cause of morbidity and mortality in hospitalised patients globally.
      Betalactams are time-dependent antibiotics, and so, the duration of time for which the free
      drug plasma concentration remains above the minimum inhibitory concentration (fT &gt; MIC) is
      the pharmacokinetic/pharmacodynamic index associated with bacterial killing and clinical
      improvement. Numerous studies have demonstrated that continuous infusion (infusion in 24
      hours) and extended infusion (through prolonging the infusion time to greater than 3 hours)
      allows the maintenance of concentrations above the MIC for a longer period of time within the
      dosing interval (30 minute or 1 hour), and so, capitalises on the pharmacodynamic properties
      of betalactams and maximises bacterial killing, therefore potentially improving clinical
      outcomes. In adult patients, the several studies suggest that prolonged infusion may offer
      clinical benefits and significant reduction in mortality without increasing the risk of
      toxicity, however, there is limited information about these dosing strategies in pediatric
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with clinical response</measure>
    <time_frame>Number of participants with clinical response at 14 days after the study drug cessation or the day of your discharge</time_frame>
    <description>Resolution. Disappearance of all signs and symptoms related to the infection. Improvement. A marked or moderate reduction in the severity and/or number of signs and symptoms of infection.
Failure. Insufficient lessening of the signs and symptoms of infection to qualify as improvement, including death or indeterminate (no evaluation possible, for any reason).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Number of participants with adverse events evaluated by an physician at the time of administration of antibiotics and 24 hours after the study drug cessation.</time_frame>
    <description>Any harmful, undesirable, potentially serious and life threatening effects occurring during or after administration of the antibiotics proposed in this study (piperacillin / tazobactam, imipenem or meropenem), evaluated by and physician and recorded in the clinical file with description of suspected adverse reaction, including exploration and laboratory data, as well as consequences of the reaction.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Intermittent Piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent Imipenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Imipenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Meropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermittent Piperacillin/tazobactam</intervention_name>
    <description>Piperacillin/tazobactam administered in 30 minutes infusion.</description>
    <arm_group_label>Intermittent Piperacillin/tazobactam</arm_group_label>
    <other_name>Intermittent Infusion of Piperacillin/tazobactam</other_name>
    <other_name>PiSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous Piperacillin/tazobactam</intervention_name>
    <description>Piperacillin/tazobactam administered in 24 hours infusion.</description>
    <arm_group_label>Continuous Piperacillin/tazobactam</arm_group_label>
    <other_name>Continuous Infusion of Piperacillin/tazobactam</other_name>
    <other_name>PiSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermittent Imipenem</intervention_name>
    <description>Imipenem administered in 60 minutes infusion.</description>
    <arm_group_label>Intermittent Imipenem</arm_group_label>
    <other_name>Intermittent Infusion of Imipenem</other_name>
    <other_name>PiSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended Imipenem</intervention_name>
    <description>Imipenem administered in 6 hours infusion.</description>
    <arm_group_label>Extended Imipenem</arm_group_label>
    <other_name>Extended Infusion of Imipenem</other_name>
    <other_name>PiSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermittent Meropenem</intervention_name>
    <description>Meropenem administered in 60 minutes infusion.</description>
    <arm_group_label>Intermittent Meropenem</arm_group_label>
    <other_name>Intermittent Infusion of Meropenem</other_name>
    <other_name>Kener</other_name>
    <other_name>Merrem, AstraZeneca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended Meropenem</intervention_name>
    <description>Meropenem administered in 8 hours infusion.</description>
    <arm_group_label>Extended Meropenem</arm_group_label>
    <other_name>Extended Infusion of Meropenem</other_name>
    <other_name>Kener</other_name>
    <other_name>Merrem, AstraZeneca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with sepsis, who have been evaluated by an infectious physician and
             are candidates to receive piperacillin/tazobactam, imipenem or meropenem as empiric
             treatment.

        Exclusion Criteria:

          -  Patients with a history of allergy to one or more of the proposed antibiotics.

          -  Patients with chronic kidney disease or acute renal failure.

          -  Patients with acute liver failure of any cause.

          -  Patients in palliative or supportive care only.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazmín del Carmen Fuentes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Salamanca</last_name>
    <phone>52(55)56-27-6900</phone>
    <phone_ext>21216</phone_ext>
    <email>carla.martinez@imss.gob.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carla Martínez</last_name>
    <phone>52(55)56-27-6900</phone>
    <phone_ext>21218</phone_ext>
    <email>carla.martinez@imss.gob.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Infantil de México Federico Gómez</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Norberto Jiménez</last_name>
      <phone>52(55)55-88-7238</phone>
      <phone_ext>2331</phone_ext>
      <email>dr.jimenezjuarez@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarbelio Moreno</last_name>
      <phone>52(55)52-28-9917</phone>
      <phone_ext>2331</phone_ext>
      <email>sarbelio.infecto@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fortino Solórzano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Guillermo Vázquez</last_name>
      <phone>52(55)56-27-6900</phone>
      <phone_ext>22462</phone_ext>
      <email>vazguill@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Ma. Guadalupe Miranda</last_name>
      <phone>52(55)56-27-6900</phone>
      <phone_ext>22507</phone_ext>
      <email>uepidemiologia@live.com.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Yazmín Del Carmen Fuentes Pacheco</investigator_full_name>
    <investigator_title>Pediatric Infectious Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Identified individual participant data for all primary and secondary outcome measures will be made available within six months of study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

